The market is segmented based on , By Product Type (Checkpoint Inhibitors, Monoclonal Antibodies, Vaccines, Cell Therapies, Immunomodulators and Oncolytic Virus), Application (Lung Cancer, Breast Cancer, Melanoma, Multiple Myeloma, Prostate Cancer, Ovarian Cancer, Cervical Cancer, Stomach Cancer, Colorectal Cancer, Head & Neck Cancer, and Others), End User (Hospitals, Oncology Clinics, Homecare, and Others), Form (Intravenous (IV), Intramuscular, and Oral), Distribution Channel (Direct Tenders, Retail Sales, and Pharmacies) - Industry Trends and Forecast to 2031.
.
The Global Cancer Immunotherapy Market size was valued at USD 83575.21 USD Million in 2023.
The Global Cancer Immunotherapy Market is projected to grow at a CAGR of 14.5% during the forecast period of 2024 to 2031.
The major players operating in the market include Merck & Co., F. HoffmannLa Roche Ltd, BristolMyers Squibb Company, Janssen Pharmaceutical, AstraZeneca, Gilead Sciences, Lilly, Amgen , Novartis AG, GSK plc., Pfizer , yte, Celldex Therapeutics, Atara Biotherapeutics, Cellectis, AbbVie , Bayer AG.
The market report covers data from the U.S., Canada, Mexico, Germany, France, Italy, Spain, U.K., Switzerland, Netherlands, Russia, Turkey, Poland, Hungary, Lithuania, Austria, Ireland, Norway and Rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Thailand, Indonesia, Philippines, Malaysia, Vietnam and Rest of Asia-Pacific, Brazil, Argentina, Peru and Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, Oman, Qatar, Bahrain and Rest of Middle East and Africa.
Corporate Email ID Only (Avoid Using Generic mail ID such as Gmail)
Consent Preferences
We use cookies to improve your experience We use cookies to deliver the best possible experience on our website. To learn more, visit our Privacy Policy. By continuing to use this site, or closing this box, you consent to our use of cookies. Cookie Notice.
The data presented is for visualization purposes only and may not reflect actual results.
